The landscape of surgical management for benign prostatic hyperplasia has been transformed by the advent of Minimally Invasive Surgical Therapies (MIST). These innovative procedures have emerged to fill the treatment gap between medical therapy and more invasive traditional surgeries like TURP and HoLEP. MIST procedures are designed to alleviate lower urinary tract symptoms (LUTS) while minimizing the side effects and morbidity associated with more invasive surgeries, particularly the risk of sexual dysfunction. This chapter provides a comprehensive review of the most common MIST procedures, including their mechanisms of action, clinical evidence, and patient outcomes.
Prostatic Urethral Lift (PUL) - The UroLift® System
The Prostatic Urethral Lift (PUL), commercially known as the UroLift System, is a non-ablative MIST procedure that mechanically retracts the obstructing prostatic lobes to open the urethral lumen. It is a unique approach that avoids cutting, heating, or removing prostatic tissue, thereby preserving sexual function.
Mechanism of Action: The UroLift system involves the transurethral placement of small, permanent implants that hold the enlarged prostatic lobes apart, much like tie-backs on a curtain. The procedure is typically performed under local or light sedation in an outpatient setting. The implants are delivered via a specialized delivery device, and the number of implants used varies depending on the size and configuration of the prostate.
Clinical Evidence and Outcomes: The efficacy and safety of the UroLift system have been well-established in several key clinical trials, most notably the L.I.F.T. (Luminal Improvement Following Prostatic Tissue Approximation for LUTS Secondary to BPH) pivotal study.
- Efficacy: The L.I.F.T. study, a multicenter, randomized, controlled trial, demonstrated that PUL resulted in a significant and durable improvement in both subjective and objective measures. Patients treated with UroLift experienced an average improvement in their International Prostate Symptom Score (IPSS) of over 50% and a 44% improvement in peak urinary flow rate (Qmax). These improvements have been shown to be sustained for up to 5 years.
- Safety and Sexual Function Preservation: A major advantage of the UroLift system is its excellent safety profile and its ability to preserve sexual function. The L.I.F.T. study reported no instances of new, sustained erectile or ejaculatory dysfunction. This makes UroLift an attractive option for sexually active men who wish to avoid the risk of retrograde ejaculation associated with traditional surgical procedures.
- Durability and Re-treatment: While UroLift is effective, it is associated with a higher re-treatment rate compared to more invasive procedures like HoLEP or TURP. Real-world data has shown re-treatment rates ranging from 4% to 13% at 5 years. Patients should be counseled about the potential need for future interventions.
Patient Selection: The ideal candidate for UroLift is a man with bothersome LUTS, a prostate volume between 30 and 80 mL, and a desire to preserve sexual function. It is particularly well-suited for patients who are not candidates for or wish to avoid more invasive surgery. The presence of a large, obstructive median lobe can be a relative contraindication, although techniques have been developed to address this.
Convective Water Vapor Thermal Therapy - The Rezūm™ System
Convective Water Vapor Thermal Therapy, commercially known as the Rezūm System, is another office-based MIST procedure that utilizes the thermal energy of water vapor to ablate prostatic tissue and reduce bladder outlet obstruction.
Mechanism of Action: The Rezūm system delivers targeted, controlled doses of sterile water vapor (steam) into the obstructive prostatic tissue. The procedure is performed transurethrally using a specialized delivery device. When the steam is injected into the tissue, it rapidly and uniformly disperses through the interstitial spaces. As the vapor condenses, the stored thermal energy is released, causing immediate and irreversible cell death. The treated tissue is then gradually absorbed by the body's natural healing response, leading to a reduction in prostate volume and an opening of the urethral channel.
Clinical Evidence and Outcomes: The efficacy and safety of Rezūm have been validated in a pivotal, randomized, controlled trial (the Rezūm II study) and numerous real-world studies.
- Efficacy: The Rezūm II trial demonstrated a significant and durable improvement in LUTS. Patients treated with Rezūm experienced a greater than 50% improvement in their IPSS, which was sustained at 5-year follow-up. A significant improvement in Qmax was also observed. Real-world studies have confirmed these findings, showing Rezūm to be effective in a broad range of patients, including those with a median lobe and those in urinary retention.
- Safety and Sexual Function Preservation: Rezūm has a favorable safety profile. The procedure is associated with minimal bleeding and a low risk of significant complications. Importantly, clinical studies have shown a low incidence of de novo erectile dysfunction and a high rate of ejaculatory function preservation. This makes Rezūm a compelling option for patients who wish to maintain their sexual function.
- Durability and Re-treatment: The 5-year data from the Rezūm II trial showed a surgical re-treatment rate of only 4.4%, demonstrating the long-term durability of the procedure. This low re-treatment rate is comparable to more invasive surgical options.
Patient Selection: Rezūm is a versatile procedure that is suitable for a wide range of patients with moderate to severe LUTS. It is indicated for the treatment of prostates with volumes from 30 to 80 mL, and it can also be used to treat patients with an obstructive median lobe. It is an excellent option for patients who are seeking a minimally invasive treatment with a low risk of sexual side effects and a durable outcome.
Aquablation - The AquaBeam® System
Aquablation therapy, delivered by the AquaBeam Robotic System, is a novel and innovative MIST procedure that combines robotic precision with the power of a heat-free waterjet to ablate prostatic tissue. It is a unique approach that offers the potential for a high degree of precision and a low risk of thermal injury.
Mechanism of Action: Aquablation is performed under general anesthesia. The procedure utilizes real-time, multi-dimensional ultrasound imaging to create a detailed map of the prostate. The surgeon then uses this map to create a personalized treatment plan, specifying the exact amount of tissue to be removed. The robotic system then executes the treatment plan, delivering a high-velocity, heat-free waterjet to ablate the targeted prostatic tissue. The combination of robotic precision and ultrasound guidance allows for a highly controlled and predictable procedure.
Clinical Evidence and Outcomes: The efficacy and safety of Aquablation have been established in a series of large, randomized, controlled trials, most notably the WATER (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) and WATER II studies.
- Efficacy: The WATER study, which compared Aquablation to TURP, demonstrated that Aquablation was non-inferior to TURP in terms of symptom improvement at 6 months. The study also showed that Aquablation was superior to TURP in terms of safety, with a lower risk of sexual side effects. The WATER II study, which evaluated Aquablation in patients with large prostates (80-150 mL), demonstrated that the procedure was safe and effective in this challenging patient population.
- Safety and Sexual Function Preservation: A key advantage of Aquablation is its ability to preserve sexual function. The WATER study reported a significantly lower rate of ejaculatory dysfunction with Aquablation compared to TURP (10% vs. 36%). This is attributed to the heat-free nature of the waterjet, which minimizes the risk of thermal injury to the delicate nerves involved in ejaculation.
- Durability and Re-treatment: Long-term data from the WATER study has shown that the excellent outcomes of Aquablation are sustained at 5-year follow-up, with a low re-treatment rate.
Patient Selection: Aquablation is a versatile procedure that is suitable for a wide range of patients with moderate to severe LUTS. It is indicated for the treatment of prostates with volumes from 30 to 150 mL. It is an excellent option for patients who are seeking a minimally invasive treatment with a low risk of sexual side effects and a durable outcome. It is particularly well-suited for patients with large prostates, where it offers a safe and effective alternative to more invasive procedures like open prostatectomy.
Comparative Analysis of MIST Procedures
The choice of MIST procedure depends on several factors, including prostate size, patient symptoms, sexual function status, and patient preferences. The following table provides a comparative overview of the three main MIST procedures discussed in this chapter.
| Feature | UroLift (PUL) | Rezūm (WVTT) | Aquablation |
|---|---|---|---|
| Mechanism | Mechanical retraction of lobes | Thermal ablation with water vapor | Heat-free robotic waterjet ablation |
| Prostate Size | 30-80 mL | 30-80 mL | 30-150 mL |
| IPSS Improvement | >50% | >50% | >50% |
| Qmax Improvement | 44% | Significant | Significant |
| Sexual Function | Excellent preservation (no retrograde ejaculation) | Excellent preservation | Excellent preservation (lowest retrograde ejaculation rate) |
| Re-treatment Rate | 4-13% at 5 years | 4.4% at 5 years | Low at 5 years |
| Anesthesia | Local/light sedation | Local/light sedation | General anesthesia |
| Procedure Time | 20-30 minutes | 30-45 minutes | 45-60 minutes |
| Hospital Stay | Outpatient | Outpatient | Outpatient or overnight |
| Median Lobe | Relative contraindication | Can be treated | Can be treated |
MIST in the Context of the Overall BPH Treatment Algorithm
The emergence of MIST procedures has expanded the treatment options available to patients with BPH and LUTS. While medical therapy remains the first-line treatment for most patients, MIST procedures offer an attractive middle ground between medical therapy and more invasive surgical options. For patients who have failed medical therapy or are intolerant to medications, MIST procedures provide an effective and minimally invasive alternative that preserves sexual function and offers a good quality of life.
However, it is important to recognize that MIST procedures are not suitable for all patients. Patients with very large prostates (>150 mL), severe symptoms, or those seeking a definitive, durable solution with the lowest possible re-treatment rate may be better served by more invasive procedures like HoLEP, TURP, or open prostatectomy. The key to optimal patient outcomes is a thorough understanding of the strengths and limitations of each procedure and a careful matching of the procedure to the individual patient's needs and preferences.
The Future of MIST
The field of MIST is rapidly evolving, with new technologies and techniques being developed and refined on a regular basis. Other emerging MIST procedures include the Temporarily Implanted Nitinol Device (iTIND), Transperineal Prostate Laser Ablation (TPLA), and Prostatic Artery Embolization (PAE). As these technologies mature and more long-term data become available, the treatment landscape for BPH will continue to expand, offering patients an ever-increasing array of options tailored to their individual needs and preferences.
The paradigm shift from the management of BPH to the management of LUTS, as emphasized by the European Association of Urology, reflects the growing recognition that the goal of treatment is not simply to reduce prostate size, but to alleviate bothersome symptoms while maintaining quality of life and sexual function. In this context, MIST procedures play an increasingly important role in the armamentarium of the modern urologist.